MetaCap

Xilio Therapeutics Inc. (XLO)

NASDAQ: XLOHealth CareBiotechnology: Pharmaceutical PreparationsUSD

7.56-0.085 (-1.11%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

XLO stock chart

Technical analysis

Key statistics

All statistics
Market cap
$53.40M
52-week range
6.47 – 10.71
Day range
7.07 – 7.60
Volume / Avg
20.10K / 11.54K
Beta
—

52-week range

$6.47$10.71

XLO stock today

Shares of Xilio Therapeutics (XLO) finished lower on Nov 20 at $7.56, a drop of 1.11% or $0.085 per share, versus the S&P 500's 3.70% decline. Shares are 29.4% below their 52-week high of $10.71, set on Nov 25, 2025 and 16.9% above the 52-week low of $6.47, in the middle of the past year's range. XLO is down 15.6% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 28.3%.

Xilio Therapeutics trades at 11.6x its trailing twelve-month earnings per share of $0.65.

Summary generated from market data by MetaCap's automated system. Methodology

About Xilio Therapeutics

Company profile

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company's pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart, an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Rene Russo BCPS, Pharm.D.
Headquarters
Waltham, MA
Employees
76
IPO year
2021

Financial highlights

Full financials

In fiscal 2025, Xilio Therapeutics generated $43.8 million in revenue, up 589.9% from fiscal 2024. Xilio Therapeutics reported a net loss of $35.0 million, compared with a loss of $58.2 million a year earlier. Operating margin was -95.9%.

Xilio Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$43.77M$6.34M———
Growth+589.88%————
Net income$-35.04M$-58.24M$-76.40M$-88.22M$-75.80M
EPS (diluted)$-4.19$-15.24$-2.78$-3.22$-13.52

Analyst forecast

Forecast

Consensus (1 analysts)

none

Avg. price target

$20.00+164.55%

  • Strong buy 0
  • Buy 1
  • Hold 0
  • Sell 0
  • Strong sell 0

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 12, 2026
EPS actual vs est.
$-0.30 vs $-1.05
Surprise
+71.43%

XLO news

All XLO news

Xilio Therapeutics peers

Health Care sector
XLO peer companies
CompanyPrice% ChgMarket capCompare
CTORCitius Oncology Inc.0.5035-10.95%$53.25Mvs XLO
XBITXBiotech Inc.1.73+2.98%$52.74Mvs XLO
LFVNLifevantage Corporation4.15-15.13%$52.63Mvs XLO
BOLDBoundless Bio Inc.2.32-2.52%$54.78Mvs XLO
AZRAzora Therapeutics Inc.3.85-0.52%$55.00Mvs XLO
ALDXAldeyra Therapeutics Inc.0.84+16.39%$50.70Mvs XLO
CLNNClene Inc.3.52+0.57%$50.69Mvs XLO
KZIAKazia Therapeutics Limited ADR4.92-8.38%$56.22Mvs XLO

Indexes, lists and sector

Xilio Therapeutics stock FAQ

What is Xilio Therapeutics's stock price today?

XLO last traded at $7.56 as of Nov 20, 4:00 PM EST, down 1.11% on the day. Prices are delayed at least 15 minutes.

Does Xilio Therapeutics pay a dividend?

No. Xilio Therapeutics does not currently pay a regular cash dividend.

What is XLO's P/E ratio?

XLO trades at a trailing P/E ratio of 11.63.

Who is Xilio Therapeutics's CEO?

Dr. Rene Russo BCPS, Pharm.D. is the chief executive officer of Xilio Therapeutics Inc., which has about 76 employees.

Has XLO ever split its stock?

Yes. The most recent XLO stock split was a 1-for-14 split on Mar 16, 2026.

What is the XLO 52-week high?

The 52-week high for XLO is $10.71 and the 52-week low is $6.47. The stock is currently 29.4% below its high.

Compare XLO